Table 1.
Patient characteristics (N = 42)
| Characteristic | N (%) |
|---|---|
| Sex | |
| Male | 19 (45) |
| Female | 23 (55) |
| Age (years) | |
| Median | 60 |
| Range | 36 to 79 |
| Race/ethnicity | |
| Caucasian | 37 (88) |
| African American | 3 (7) |
| Other | 2 (5) |
| ECOG performance status | |
| 0 | 15 (36) |
| 1 | 27 (64) |
| Prior adjuvant therapy | 2 (5) |
| Gemcitabine-baseda | 1 (50) |
| Chemoradiationb | 1 (50) |
| Disease stage | |
| III | 2 (5) |
| IV | 40 (95) |
| Site of metastasis (N = 40) | |
| Liver only | 29 (73) |
| Liver + other | 2 (5) |
| Other only | 9 (23) |
| CA19-9 | |
| Normal (≤37 U/ml) | 6 (14) |
| Elevated (>37 U/ml) | 36 (86) |
| Albumin | |
| Normal (≥3.4 g/dl) | 28 (67) |
| Low (<3.4 g/dl) | 14 (33) |
aPatients developed recurrence/metastases while on a clinical trial of gemcitabine ± Saccharomyces cerevisiae vaccine.
bPatients were treated on a clinical trial of 5-FU, cisplatin, interferon-α, and radiation.